Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MUSA: Mid-urethral Sling vs. Botox A for Mixed Urinary Incontinence
NCT04171531Phase 3Completed
- Sponsor
- Pelvic Floor Disorders Network
- Start
- Jun 2020
- Primary completion
- Feb 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of botulinum toxin type A in mixed urinary incontinence (MUI) (2 arms), sponsored by Pelvic Floor Disorders Network. Primary endpoint: Urogenital Distress Inventory - Long Form Total Score Change From Baseline at 12 months. Started Jun 2020; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
mixed urinary incontinence (MUI)
Beyond the preview
Go deeper on NCT04171531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04171531.